Research programme: pyridazinone anti-psychotic therapeutics - Egis Pharmaceuticals/Servier

Drug Profile

Research programme: pyridazinone anti-psychotic therapeutics - Egis Pharmaceuticals/Servier

Alternative Names: EGIS-11148

Latest Information Update: 14 Sep 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Egis Pharmaceuticals
  • Developer Egis Pharmaceuticals; Servier
  • Class Ketones; Pyridazines
  • Mechanism of Action Alpha 1 adrenergic receptor modulators; Alpha 2 adrenergic receptor agonists; Alpha-2 adrenergic receptor modulators; Dopamine D2 receptor modulators; Serotonin 2A receptor modulators; Serotonin-6 receptor modulators; Serotonin-7 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Psychotic disorders; Schizophrenia

Most Recent Events

  • 03 Sep 2008 Pharmacodynamics data from a preclinical trial in Psychotic disorders presented at the 21st Annual Congress of the European College of Neuropsychopharmacology (ECNP-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top